Semaglutide vs. tirzepatide: do the side effect claims hold up?

What did @glp1nphaley actually say?

The core argument here is pretty straightforward: semaglutide is cheaper but comes with more GI side effects, while tirzepatide costs more but delivers better weight loss with fewer side effects. The creator, who identifies as a GLP-1 prescribing nurse practitioner, says "the vast majority of my patients on tirzepatide don't experience any side effects at all," and frames tirzepatide as "the best medicine" if cost isn't a concern. They attribute the side effect difference to receptor pharmacology, noting semaglutide hits one receptor while tirzepatide hits two.

The video is clinically opinionated in a way that's actually useful. It's not vague. It makes testable claims about efficacy, tolerability, and mechanism. That makes it worth checking carefully.

Does the science back this up?

Mostly yes, with some important caveats. The receptor pharmacology claim is accurate. Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts only on GLP-1 receptors. That dual mechanism does appear to drive superior weight loss outcomes in head-to-head data.

The SURMOUNT-5 trial (Jastreboff et al., 2025, NEJM) is the most relevant direct comparison. It found tirzepatide produced roughly 20.2% body weight reduction compared to 13.7% with semaglutide over 72 weeks in adults with obesity. That's a clinically meaningful gap, not a marginal one. On side effects, both drugs produced similar rates of GI adverse events in that trial, though discontinuation due to GI issues was numerically lower with tirzepatide. Earlier phase 3 data from the SURPASS and SUSTAIN programs also showed broadly similar GI tolerability profiles between the two agents, not the dramatic contrast this creator describes from clinical practice.

What did they get wrong (or right)?

The weight loss hierarchy is right. The mechanism explanation is right. The cost framing is generally right, though pricing varies widely by insurance, compounded access, and manufacturer coupons.

Where this gets shaky is the side effect comparison. Saying "the vast majority of my patients on tirzepatide don't experience any side effects at all" is a clinical anecdote, not a finding from controlled data. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed nausea occurred in roughly 32% of patients on tirzepatide 15mg. That's not trivial. The claim that semaglutide reliably causes more GI side effects than tirzepatide is not cleanly supported in the published literature. SURMOUNT-5 did not show a statistically significant difference in GI discontinuation rates between the two drugs.

The creator also lists constipation alongside diarrhea for semaglutide, which is accurate since slowed gastric motility can go either direction. That nuance is often missed, so credit there.

What should you actually know?

If you're comparing these two medications, a few things matter more than this video covers. First, individual response to GLP-1 medications varies significantly. Some patients have zero nausea on semaglutide and miserable nausea on tirzepatide. Clinical anecdote from a single prescriber's panel, however experienced, isn't the same as population-level data.

Second, the "best medicine" framing deserves scrutiny. Tirzepatide does outperform semaglutide on average weight loss in trials, but "best" depends on your health history, comorbidities, insurance coverage, and how your body responds. Patients with certain GI conditions may tolerate one drug very differently from another.

Third, neither drug is appropriate to evaluate or start without a qualified prescriber reviewing your full medical history. This video is general guidance, not a substitute for that conversation. And if you're considering compounded versions of either medication, understand that compounded GLP-1 drugs are not FDA-approved and are not equivalent to brand-name products in terms of regulatory oversight or verified potency.

The bottom line

This is a reasonably well-informed take from someone who clearly works with these medications daily. The receptor pharmacology is correct, the weight loss hierarchy is supported by controlled trial data, and the cost framing reflects real-world experience. The side effect comparison is where the video oversimplifies. Clinical practice patterns from one prescriber's population do not override the phase 3 trial data, which shows both drugs carry meaningful GI side effect profiles. Tirzepatide may have a slight tolerability edge at some doses, but "the vast majority don't experience any side effects at all" is not what the controlled studies show.